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Background: The aberrant methylation of CpG islands in the promoter is associated with colorectal cancer (CRC)
carcinogenesis. In our previous study, the promoter of alcohol dehydrogenase, iron containing, 1 (ADHFE1) was
most highly methylated in CRC compared to normal colorectal mucosa. In this study, we examined the expression
and function of the ADHFE1 in CRC.
Methods: We examined the promoter methylation and mRNA expression of ADHFE1 with 5-aza-20-deoxycytidine
(5-Aza-2-dC) in 12 CRC cell lines, 124 paired CRC and adjacent normal mucosa, and 59 advanced adenomas. To
confirm methylation of ADHFE1, we performed bisulfite genomic sequencing in 3 CRC cell lines, 6 paired CRC and
adjacent normal mucosa. ADHFE1 protein expression was studied using western blot and immunohistochemistry,
respectively in the 36 and 243 paired CRC and adjacent normal tissue. We transfected the DLD-1 with pcDNA3.1
vector containing ADHFE1 and examined the expression of differentiation marker, such as ALP, CEA and Cdx2. We
examined the ADHFE1 expression at distinct developmental stages in mouse embryos.
Results: The ADHFE1 promoter was hypermethylated in all CRC cell lines, 81.8% in CRCs, and 84.7% in advanced
adenomas, with reciprocal change by 5-Aza-2-dC. The expression of ADHFE1 mRNA was down-regulated in all
CRC cell lines and 96.3% in CRC tissues. The expression of ADHFE1 protein was down-regulated in 91.7% of CRC
tissues. In the immunohistochemistry, normal epithelial cells at the crypt top showed very strong ADHFE1
expression, whereas they were much weaker at the crypt base. In CRC, the good differentiation was significantly
associated with high ADHFE1 expression. The activity of differentiation marker, such as ALP and CEA, was higher
in pcDNA3.1-ADHFE1 transfected CRC cells with consistent correlation with ADHFE1 protein than control. In
mouse embryos, ADHFE1 in the large intestine was the first detected at E15.5. At E18.5, ADHFE1 was
predominantly expressed in the top of the mature crypt epithelium.
Conclusions: It showed that the hypermethylation of ADHFE1 promoter in CRC is concordance with down-regulation
of ADHFE1 mRNA and ADHFE1 protein. ADHFE1 has an important role of differentiation in CRC, as well as normal
colorectal mucosa and embryonic developmental processes.
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Table 1 Clinical characteristics of the study population
CRC (n = 124)
Age, years
Mean ± SD 58.9 ± 9.97
Median (range) 60.0 (32–77)
Gender (%)
Male/Female 77 (62.1)/47 (37.9)
Location (%)
Right/Left side 64 (51.6)/60 (48.4)
Differentiation (%)
Well/Moderate/Poorly 13 (10.5)/92 (74.2)/19 (15.3)
Duke stage (%)
I/II/III/IV 4 (3.2)/64 (51.6)/45 (36.3)/11 (8.9)
Microsatellite instability status (%)
MSS/Low MSI/High MSI 107 (86.2)/8 (6.5)/9 (7.3)
Advanced adenoma (n = 59)
Age, years
Mean ± SD 46.5 ± 1.74
Median (range) 40.0 (17–72)
Gender (%)
Male/Female 47 (79.7)/12 (20.3)
Size, mm
Mean ± SD 17.4 ± 0.92
Median (range) 15.0 (0.7-35)
Location (%)
Right/Left side 20 (33.9)/39 (66.1)
Histology (%)
Tubular/Tubulovillous/Villous 39 (66.1)/19 (32.2)/1 (1.7)
Grade of dysplasia (%)
Low/High 49 (83.1)/10 (16.9)
CRC, colorectal cancer; SD, standard deviation; MSS, microsatellite stability;
MSI, microsatellite instability.
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Colorectal cancer (CRC) is one of the leading causes of
cancer-related death in the world, in spite of the avail-
ability of colonoscopy screening and effective prevention
through a colorectal adenoma resection. Recent evidence
indicates that epigenetic alterations, apart from genetic
alteration, play an important mechanism in CRC carcino-
genesis [1]. Epigenetic alterations are potentially revers-
ible in neoplasia, and they present new opportunities for
the clinical management of cancer, which are different
from mutation [2]. The most common epigenetic alter-
ation in CRC is aberrant DNA methylation, in which a
methyl group is added to the cytosine base in the di-
nucleotide sequence CpG islands, which are often associ-
ated with the promoter [1,2]. Methylation in a gene
promoter region generally correlates with a silenced gene
[2]. Several genes involved in CRC carcinogenesis found
to be silenced by DNA methylation include: MCC,
MLH1, MGMT, APC, hMLH1, GATA-4, GATA-5, TFPI2,
and SOX17 [2-8].
The iron-activated alcohol dehydrogenase family had
seemed to only exist in microbial organisms until Mao
et al. cloned alcohol dehydrogenase, iron containing, 1
(ADHFE1) from a human fetal brain cDNA in 2002
[9]. About 10 years later, just as there are only a few
more studies [10,11]. Kim et al. showed that ADHFE1
transcript exhibits differentiation-dependent expression
during in vivo brown and white adipogenesis [10]. An-
other study indicated that ADHFE1 is related to bacterial
γ-hydroxybutyrate dehydrogenase and has a conserved
NAD-binding site [11]. Recently, we had documented
gene profiles with promoter hypermethylation using Hu-
man Methylation27 DNA Analysis BeadChip in CRC
[12]. Among these genes, the ADHFE1 gene is the most
highly methylated in CRC compared to normal colorectal
mucosa and the expression is down-regulated more than
twofold [12]. It was also reported that the ADHFE1 pro-
moter is hypermethylated in CRC and adenoma by an-
other research group [13].
Here, we investigated ADHFE1 promoter methylation
in CRC cell lines and CRC tissues. Additionally, we




One hundred twenty four CRC and 59 advanced aden-
oma tissues greater than 1 cm in diameter and/or with
a villous component and/or with severe dysplasia were
collected from patients treated at Samsung Medical
Center, Seoul, Korea (Table 1). We also retrieved 124 adja-
cent normal colorectal mucosa tissues from CRC patients.
None of the patients had clinically apparent polyposis syn-
drome or hereditary nonpolyposis colon cancer syndrome.Written informed consent was obtained from all patients.
This study was reviewed and approved by the Samsung
Medical Center Institutional Review Board in accordance
with the Declaration of Helsinki.
CRC cell lines and 5-aza-20-deoxycytidine (5-aza-2-dC)
treatment
We used CoLo205, DLD-1, HT15, HT116, HT29,
KM12C, KM12SM, KM20, RKO, SNU81, SW48 and
WiDr as human CRC cell lines. Each of the CRC cell
lines were treated for 48 hours with 0 or 2 μM 5-aza-2-
dC (Sigma-Aldrich, St. Louis, Mo, USA).
DNA extraction and bisulfite modification
Genomic DNA was extracted using the QIAamp tissue
kit (Qiagen, Valencia, CA, USA). A bisulfite conversion
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(Zymo Research, Irvine, CA, USA) according to the
manufacturer’s protocol. DNA was extracted from tumor
cells or the epithelial layer of formalin-fixed, paraffin
embedded tissue sections.
Quantitative real time PCR (RT-PCR) to measure DNA
methylation (MethyLight)
The ADHFE1 gene presents on human chromosome 8q
13.1. The promoter region of the ADHFE1 gene contains
a dense CpG island located from nucleotides −257 to +265
relative to translation start site (TSS). We examined 12
CRC cell lines and CRC tissues using methylation-
specific PCR with primers located from −4 to +102 rela-
tive to TSS.
After bisulfite conversion of the same amount of
DNA solution, ALU-based MethyLight control reaction
was done to quantify the number of input target
DNA, and the threshold cycle values were confirmed
to be comparable among DNA samples. The primer
and probe sequences used were as follows: ADHFE1
forward primer: 5-CGTTATGGTCGTTGTCGTTC-30,
ADHFE1 probe: 6FAM-CGCCGACCCCGCACTCAC
GC-MGBNFQ, ADHFE1 reverse primer: 5-GTAAACA
CCCTACGATCCCCTACCCG-3. ALU forward primer:
5-GGTTAGGTATAGTGGTTTATATTTGTAATTTTA
GTA-3, ALU probe: 6FAM-CCTACCTTAACCTCCC-
MGBNFQ, ALU reverse primer: 5-ATTAACTAAAC
TAATCTTAAACTCCTAACCTCA-3.
MethyLight was performed by using a 7900HT Real-
Time PCR system (Applied Biosystems, Foster City,
CA, USA). The PCR program was as follows: 5 minutes
at 95°C, followed by 45 cycles of 30 seconds at 95°C,
30 seconds at 60°C, and 30 seconds at 72°C. CpGenome™
universal methylated and unmethylated DNA (Chemicon,
Temecula, CA, USA) were used as a positive control for
the methylated and unmethylated genes, respectively. The
percentage of methylated reference (PMR) at a specific
gene was calculated by dividing the GENE/ALU ratio of a
sample by the GENE/ALU ratio of the in vitro fully methyl-
ated placental DNA and multiplying by 100. We used the
PMR cut-off value more than 10% to define methylation-
positive vs. negative and determined DNA methylation fre-
quencies for each CpG island locus.
Bisulfite genomic sequencing
We performed bisulfite genomic sequencing for CRC
tissue, and adjacent normal colorectal mucosa according
to the manufacturer’s instructions. We performed PCR
to amplify the sequence for CpG island located in the
promoter lesion and TSS using the following primer
sets: BS1F (50-TTTGAAAAATAAGATATAGTGTTTAA
TTAT-30) and BS1R (50-AAATAACTCTAAACTCAACA
AAAAC-30); BS2F (50-GTTTTTGTTGAGTTTAGAGTTATTT-30) and BS2R (50-ACCACTACCCCAAAATT
ACAC-30). The PCR assays were performed at 95°C for
15 minutes, 45 cycles of 92°C for 30 seconds, 50 (BS1)
or 57 (BS2)°C for 45 seconds, 72°C for 30 seconds,
followed by a final extension at 72°C for 10 minutes.
PCR products were cloned using One ShotW TOP10 kit
(Invitrogen, Carlsbad, CA, USA) and sequenced using
3730xl DNA analyzer (Applied Biosystems, Foster City,
CA, USA).
RT-PCR
Two μg of total RNA was reverse transcribed by
M-MuLV reverse transcriptase with Oligo(dT)16 as a
primer. RT-PCR was performed on the ABI PRISM
7900 sequence detection system (Applied Biosystems,
Foster City, CA, USA) by monitoring the increase of
fluorescence by the binding of SYBR Green (TaKaRa,
Otsu, Japan) to double-stranded DNA. A dissociation ana-
lysis was performed at the end of each PCR reaction to en-
sure there was only a specific product. The settings for the
PCR thermal profile were as follows; initial denaturation at
95°C for 5 minutes, followed by 45 amplification cycles of
95°C for 10 seconds, annealing at 55°C for 10 seconds, and
elongation at 72°C for 30 seconds. The primer and probe
sequences used were as follows: ADHFE1 forward primer:
5- CACTGCCAGGATCCAAGATG −30, ADHFE1 reverse
primer: 5- GAGCTTTGGGGAATTTCCTG −3. GAPDH
forward primer: 50 - CCACCCATGGCAAATTCCATGG
CA - 30, GAPDH reverse primer: 50 - TCTAGACGGCA
GGTCAGGTCCACC -30. Each PCR was run in triplicate.
For quantification of gene expression changes, the ΔΔCt
method was used to calculate relative fold changes normal-
ized against the GAPDH gene.
Western blot
Cells lysates were prepared in ice-cold RIPA buffer
(0.5% sodium deoxycholate, 1% Nonidet P-40, 150 mM
NaCl, 50 mM Tris (pH 7.5), 0.1% SDS, and 1 mM
PMSF) and cleared by microcentrifugation (14 000 rpm
for 30 min at 4°C). The protein concentration in
each sample was estimated by BCA Assay. Twenty to
thirty μg of each protein sample was resolved by 12%
SDS–polyacrylamide gel electrophoresis, and electro-
blotted into nitrocellulose membranes. After 1 hour
incubation in blocking solution (5% non-fat milk in
TBST), it was incubated with primary antibodies over-
night at 4°C. The primary antibodies included: those
against ADHFE1 (1:1000) (Sigma-Aldrich, St. Louis,
MO, USA), carcinoembryonic antigen (CEA) (1:1000),
caudal type homeobox 2 (Cdx2) (1:1000) (Cell Signal-
ing, Danvers, MA, USA) and β-actin (1:5000) (Santa
Cruz Biotchology, Santa. Cruz, CA, USA). The blots
were then washed in TBST and incubated with HRP-
conjugated secondary antibodies for 1 hour at room
Tae et al. BMC Cancer 2013, 13:142 Page 4 of 10
http://www.biomedcentral.com/1471-2407/13/1/142temperature. The results were visualized using an
ECL system (Amersham Pharmacia Biotech, Arlington
Heights, IL, USA).
Immunohistochemistry
To confirm the ADHFE1 protein expression in CRC and
adjacent normal colorectal mucosa, we performed immu-
nohistochemical analysis of ADHFE1 protein expression in
243 CRC cohort groups. Immunohistochemistry was
performed on formalin-fixed, paraffin-embedded tissue
sections (4 μm thick). Sections were deparaffinized in xy-
lene, rehydrated, and incubated with 0.3% hydrogen perox-
ide in methanol for 30 minutes. The sections were placed
10 mM Tris + 1 mM EDTA with a subsequent microwave
antigen retrieval procedure. The sections were incubated
with 4% BSA +Dextran/PBST to block nonspecific anti-
body binding, followed by incubation with the primary
anti-ADHFE1 polyclonal antibody (Sigma-Aldrich, St.
Louis, MO, USA) diluted 1:2500 in PBS with 0.1% Tween
and 0.5% BSA. Sections were incubated with secondary
antibody against HRP-conjugated-rabbit Ig, and bound
antibody was visualized using 3, 3-diaminobenzidine sub-
strate as a chromogen (Dako, Copenhagen, Denmark)
followed by hematoxylin counter staining.
To assess ADHFE1 expression during mouse gut differ-
entiation and development, six pregnant female mice
(Orient Bio Inc., Seongnam, Korea). On 15, 17 and 18 days
after implantation, mice were killed by CO2 inhalation, and
each embryo was resected and frozen in liquid nitrogen for
ADHFE1 immunohistochemistry. The immunohistochem-
istry method was the same as above. Mice were handled at
the institute’s (Samsung Medical Center, Seoul, Korea) ani-
mal facility, and all treatments were in accordance with the
legal and institutional guidelines.
Immunoreactivity score (IS) in CRC tissues
In this study, we used the scoring method of Sinicrope
et al. for evaluation of both the intensity of immunohisto-
chemical staining and the proportion of stained epithelialFigure 1 The percentage of ADHFE1 methylated reference of CRC line
promoter was hypermethylated in all CRC cell lines.cells [13]. The staining intensity was further classified as
follows: weak, moderate, or strong. Positive cells were
quantified as a percentage of the total number of epithe-
lial cells and were assigned to one of the following five
categories: 0, <5%; 1, 5%–25%; 2, 26%–50%; 3, 51%–
75%; and 4, >75%. The percentage of positivity of epi-
thelial cells and staining intensities were then multiplied
to generate the IS for each case. For example, if the
staining intensity was strong and the percentage of posi-
tive cells was greater than 75%, then the IS would be
3 × 4 = 12. As a result, the IS range was from 0 to 12.
Each lesion was examined and scored by one pathologist
(SHK). In the evaluation, membranous staining was con-
sidered positive.
Cell culture and transfection
DLD-1 was cultured in IMDM (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% heat-inactivated fetal
bovine serum (Invitrogen, Carlsbad, CA, USA). The full-
length ADHFE1 cDNA (Origene Technologies, Inc.,
Rockville, MD, USA) was subcloned into a pcDNA3.1(−)
vector (Invitrogen, Carlsbad, CA, USA) to create
pcDNA3.1(−)-ADHFE1. DLD-1 was transfected with
pcDNA3.1(−)-ADHFE1 or empty vector (pcDNA3.1(−)) by
using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol.
Alkaline phosphatase (ALP) activity assay
ALP activity was determined according to the manufac-
turer’s protocol (Cell biolabs Inc., San Diego, CA, USA).
DLD-1cells were seeded into 12 well plates at
3×105cells/ml. After 72 hours, we gently aspirated the
medium from the cells and washed the cells twice with
cold PBS. Cells were lyzed in Cell Lysis Buffer (each
0.2 mL for 12 well dishes), incubated for 10 minutes
at 4°C and removed from the solution and the cell
debris spun down at 12,000 × g for 10 minutes. We
performed a BCA assay to determine the protein con-
centration of the cell lysate. We added 50 μL of cells. All CRC cell lines showed more than 10% PMR. The ADHFE1
Table 2 ADHFE1 hypermethylation and tumor type
Type of tissue Number of tissue (%) p value
Methylated Unmethylated
CRC 101 (81.5) 23 (18.5) <0.001
Advanced adenoma 50 (84.7) 9 (15.3)
Normal colon 10 (8.1) 114 (91.9)
CRC, colorectal cancer.
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wells containing 50 μL Cell Lysis Buffer. We added 50 μL
of StemTAG™ AP Activity Assay Substrate and incu-
bated for 10–30 minutes at 37°C. After stopping the reac-
tion by adding 50 μL of 1X Stop solution, we read the
absorbance of each well at 405 nm.
Statistics analysis
Statistics were calculated using SPSS software (SPSS
v.20.0; IBM Corp., Armonk, NY, USA). Continuous data
are presented as a mean ± standard deviation. Categor-
ical data are presented as percentages. The comparison
of IS among each group was evaluated using the
Kruskal-Wallis H test because of the skewed distribu-
tion. For all tests, a p value < 0.05 was considered statis-
tically significant. The difference in the continuous data
of ALP activity assay among categorized groups was
evaluated using Mann–Whitney U test because of a
skewed distribution.
Results
Correlation between ADHFE1 promoter methylation and
ADHFE1 down-regulation in CRC cell lines
To assay the aberrant DNA methylation of ADHFE1, we
examined the 12 CRC cell lines by methylation-specific
PCR. Despite being somewhat different, all 12 CRC cell
lines showed more than 10% PMR (Figure 1). After the
treatment of 5-aza-2-dC, we could observe the definite
demethylating effect of 5-aza-2-dC in 9 of 12 CRC cellFigure 2 ADHFE1 promoter methylation and mRNA expression with and
the relative methylation of ADHFE1 promoter was decreased in 9 of 12 CRC ce
was increased in 11 of 12 CRC cell lines.lines with the exception of KM12SM, KM20 and WiDr.
Also, we measured the expression of ADHFE1 mRNA in
12 CRC cell lines to investigate whether promoter methyla-
tion was associated with the inhibition of gene expression.
After 5-aza-2-dC treatment, the expression of ADHFE1
mRNA was up-regulated except SW48 (Figure 2).
Correlation between ADHFE1 promoter methylation and
ADHFE1 down-regulation in CRC tissues
To examine the methylation status of the ADHFE1 pro-
moter in 124 paired CRC tissue and adjacent normal
colorectal mucosa, and 59 independent advanced aden-
oma tissues, we performed methylation-specific PCR.
The prevalence of ADHFE1 promoter methylation in
CRC and advanced adenoma was higher as compared
with adjacent normal colorectal mucosa (Table 2). In
addition, we examined whether methylation of the CpG
Island in the ADHFE1 promoter is associated with gene
silencing by ADHFE1 mRNA expression in the 27 paired
CRC tissue and adjacent normal colorectal mucosa.without treatment with 5-aza-2-dC. (A) After treatment of 5-aza-2-dC,
ll lines. (B) After treatment of 5-aza-2-dC, the expression of ADHFE1 mRNA
Figure 3 The expression of ADHFE1 protein in CRC. A western blotting analysis was performed to examine ADHFE1 protein expression in CRC (T)
and adjacent normal colorectal tissue (N). These 8 blots are representative. The corresponding reprobings of these blots with actin as a loading control.
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cosa, the expression of ADHFE1 mRNA was down-
regulated in 96.3% (26/27) of CRC tissue. In addition, we
analyzed the ADHFE1 protein expression in 36 paired
CRC tissues and adjacent normal colorectal mucosa
using a western blot. The expression of the ADHFE1
protein was down-regulated in 91.7% (33/36) of the CRC
tissue. Therefore, it confirmed that the down-regulation
of ADHFE1 in CRC tissues was significant compared to
adjacent normal colorectal mucosa (Figure 3).
Bisulfite genomic sequencing
To confirm the methylation-specific PCR results in CRC
cell lines and tissues, we selected 6 paired CRC and adja-
cent normal colorectal mucosa, and 3 CRC cell lines,
such as WiDr, HT 116 and HT29, which had shown
hypermethylation of ADHFE1 promoter in methylation-
specific PCR. As shown in Figure 4, a good association
was seen between the methylation status, as assessed by
methylation-specific PCR and the bisulfite sequence of
the ADHFE1 promoter.
Localization of ADHFE1 protein determined by
immunohistochemistry in CRC and normal colorectal
mucosa
ADHFE1 localization in the normal colorectal mucosa is
confined to the surface epithelium and crypt top, and
cells in the crypt base are unreactive. In other words, the
intensity of ADHFE1 staining varied from the basal com-
partment to the top of the crypt epithelium. Epithelial
cells at the crypt top showed a very strong ADHFE1Figure 4 The bisulfite genomic sequencing of the ADHFE1 promoter r
unfilled (white) circles correspond to unmethylated CpG Island.expression, whereas ADHFE1 staining was much weaker
or none at the crypt base (Figure 5A). ADHFE1 staining
was also seen on the proximal colon or terminal ileum in
the regions where the presence of Paneth cells had a role
in differentiation (Figure 5B). Given the differentiation
gradient present from the basal compartment to the top
of the crypt epithelium, ADHFE1 expression seemed
modulated during differentiation.
In CRC, ADHFE1 reactivity was seen throughout the
crypt. These findings were different from those of nor-
mal mucosa. Samples were divided into three categories
according to the differentiation. The good differentiation
level was significantly associated with high ADHFE1 ex-
pression (Figure 6).
Differentiation marker analysis after pcDNA3.1-ADHFE1
transfection
To investigate the function of ADHFE1, we selected a
DLD-1 among the CRC cell lines, without expression of
ADHFE1. We transfected the DLD-1 with pcDNA3.1
vector containing the coding region of ADHFE1. To sub-
stantiate this finding, the level of differentiation marker,
including ALP, CEA and Cdx2, were determined. The
activity of ALP was higher in pcDNA3.1-ADFHE1
transfected cell colons compared with the empty vector
transfectants and the parental cells with consistent cor-
relation with ADHFE1 protein. The difference was sta-
tistically significant with a p value of < 0.05. Similarly,
the expression of CEA was up-regulated in cell clones.
In addition, the expression of Cdx2 had tended to be
up-regulated in cell colons, but there was no significantegion. Filled (black) circles correspond to the methylated CpG Island,
Figure 5 Localization of ADHFE1 in normal colorectal mucosa (×200). (A) The ADHFE1 expression was detected predominantly in the apex of the
crypts. It was noted to be decreased toward the bottom of the crypts. (B) A strong expression of ADHFE1 can be observed in the Paneth cells (arrow).
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that the expression of ADHFE1 induces CRC cell differ-
entiation (Figure 7).
ADHFE1 expression during mouse guts differentiation
and development
To gain insight into the role of ADHFE1 in embryo de-
velopment and differentiation, we examined the
ADHFE1 expression using immunohistochemistry at dis-
tinct developmental stages such as E15.5, E17.5 and
E18.5. In mouse embryos, ADHFE1 expression of the
large intestine was first detected at E15.5 (Figure 8A).Figure 6 The expression of ADHFE1 according to the differentiation s
expression of ADHFE1. (A), well differentiated CRC; (B), moderate differentia
between ADHFE1 expression and differentiation status in CRC. (E) A repres
gradient of differentiation in CRC (×100). MD, moderate differentiated CRC;This pattern was weak in the scattered cells of a devel-
oping gut. Additional expression began as the gut devel-
oped. At E17.5, the heaviest expression occurred with
crypt formation (Figure 8B). At E18.5, ADHFE1 was pre-
dominantly expressed on the top of the mature crypt
epithelium (Figure 8C). Collectively, these data suggest
strongly that ADHFE1 may play a role in development
and differentiation of embryo gut.
Discussion
We report that the ADHFE1 gene is frequently
hypermethylated in CRC cell lines and tissues, usingtatus in CRC. (A-C) Good differentiation is associated with the strong
ted CRC; (C), poorly differentiated CRC (×5). (D) There is a correlation
entative case shows a simultaneously taken picture with a different
WD, well differentiated CRC.
Figure 7 The overexpression of ADHFE1 induces the expression of a colon differentiation marker. (A) The ALP activity was increased in
the DLD-1 cell line transfected with pcDNA3.1 vector containing the coding region of ADHFE1, compared to controls. (B) The expression of
ADHFE1, CEA and Cdx2 is increased in the DLD-1 cell line transfected with pcDNA3.1 vector containing the coding region of ADHFE1 and controls.
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cing. ADHFE1 mRNA levels are frequently down-
regulated in CRC cell lines and tissues. When dense
methylation of the ADHFE1 promoter was restored after
5-aza-2-dC treatment, expression of ADHFE1 mRNA
and ADHFE1 protein had increased. Therefore we
confirmed that ADHFE1 methylation is under epigenetic
regulation. In our study, some CRC cell lines such as
KM12SM, KM20 and WiDr didn’t have the 5-aza-2-dC
effect. Mossman D et al. found that 5-aza-2-dC in-
duces gene expression, but is not necessarily
dependent on DNA demethylation [14]. Therefore, all
CRC lines didn’t observe the definite demethylating ef-
fect of 5-aza-2-dC in our study. In addition, the SW48Figure 8 The expression of ADHFE1 during mouse intestinal different
is found in the early stage of gut at E15.5 (×5). (B) With progressive villous
of epithelium at E17.5 (×5). (C) At E18.5, ADHFE1 expression is more delinecell line had periods of rapid re-methylation and res-
toration with exposure of 5-aza-2-dC [14]. It is pos-
sible that the increased ADHFE1 mRNA by 5-aza-2-dC
in the SW 48 cell line was not detected.
According to the results of immunohistochemical
staining, ADHFE1 expression is significantly reflected by
the state of differentiation in CRC tissue. ADHFE1 ex-
pression in well differentiated CRC tissues was more in-
tense than that in poorly differentiated CRC tissues, with
statistical significance. We could confirm this finding
from a representative case that simultaneously showed
well and moderately differentiated CRC cells. In addition,
ADHFE1 is expressed at the top of the colon with a de-
creasing gradient toward the crypt along the colon cryptiation and development. (A) A broad and diffuse staining of ADHFE1
formation, ADHFE1 is expressed along the whole anterior-posterior axis
ated in the top of the epithelium as differentiation proceeds (×20).
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ADHFE1 is also associated with the differentiation of
normal colon epithelium. To obtain more information
about the expression of ADHFE1 protein in embryo, we
performed an immunohistochemical analysis according
to respective mouse embryo steps. Our expression study
showed that the ADHFE1 protein is highly related to
mouse embryogenesis. Even though the data is not
shown, ADHFE1 is expressed in the organs with active
morphogenetic activities, such as the gut, lung, kidney
and several glandular structures. In a mature embryo gut,
ADHFE1 exhibits different expression patterns along the
anterior-posterior axis of the gut. At E18.5, ADHFE1 ex-
pression is confined to the ventral part of gut. It is similar
to ADHFE1 expression in the mature gut. Although im-
munohistochemical analysis is not a quantitative strategy,
it was informative enough and a discernible method to
show ADHFE1 expression in the epithelial cell layer of
mouse embryo. Therefore, it seems that ADHFE1 may
play a role in the differentiation and development of the
developing gut in mouse embryo.
To confirm the association between ADHFE1 and dif-
ferentiation, we choose DLD-1 CRC cell line without en-
dogenous ADHFE1 expression. The DLD-1, a typical
poorly differentiated CRC cell line, has been known to
have no endogenous CEA and ALP [15,16]. We con-
firmed the role of ADHFE1 for the increase of a well-
known colon epithelium differentiation marker, such
CEA and ALP [17]. Cdx2 is a caudal-related homeobox
transcription factor. Unlike CEA and ALP, DLD-1 is well
known to express Cdx2 [18]. Therefore, we might be
able to find the definite difference of Cdx2 expression
between the vector and ADHFE1-transfected cells [18].
Although it was not same focus, Kim et al. have shown
a differentiation-dependent expression of ADHFE1 in
adipogenesis [10].
Conclusions
We first report that the hypermethylation of ADHFE1
promoter in CRC is in concordance with the down-
regulation of ADHFE1 mRNA and protein. ADHFE1
protein has an important role in cell differentiation of
normal colorectal mucosa and embryonic developmental
processes. In addition, epigenetic inaction of ADHFE1
modulates cell differentiation in CRC.
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